Short Communication

iMedPub Journals
www.imedpub.com

British Biomedical Bulletin
ISSN 2347-5447

2025
Vol.13 No.1: 88

Molecular Insights into Antimicrobial Resistance: Challenges and Future Strategies

Priya Sarma*

Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India

Corresponding author: Priya Sarma, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India, E-mail: priya.sarma@ae.edu.in

Received date: January 02, 2025, Manuscript No. ipbbb-25-20758; **Editor assigned date:** January 04, 2025, PreQC No. ipbbb-25-20758 (PQ); **Reviewed date:** January 18, 2025, QC No. ipbbb-25-20758; **Revised date:** January 24, 2025, Manuscript No. ipbbb-25-20758 (R); **Published date:** January 31, 2025, DOI: 10.36648/2347-5447.13.1.88

Citation: Sarma P (2025) Molecular Insights into Antimicrobial Resistance: Challenges and Future Strategies. Br Biomed Bull Vol.12 No.1: 88.

Introduction

Antimicrobial resistance (AMR) has emerged as one of the most pressing global health crises of the 21st century, threatening to undermine decades of medical progress in treating infectious diseases. The rise of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) pathogens has led to prolonged illnesses, higher mortality rates, and increased healthcare costs. At the heart of this phenomenon are molecular mechanisms that allow bacteria, fungi, viruses, and parasites to evade or neutralize antimicrobial agents. These mechanisms are not only a product of natural evolutionary pressures but also a direct consequence of human practices such as overuse of antibiotics in medicine and agriculture. Understanding the molecular basis of AMR is therefore essential for developing innovative therapies and strategies to combat this growing threat [1].

Description

One of the most well-characterized molecular mechanisms of AMR involves enzymatic degradation or modification of drugs. β-lactamases, for instance, hydrolyze the β-lactam ring of penicillins and cephalosporins, rendering them ineffective. The emergence of Extended-Spectrum β-Lactamases (ESBLs) and carbapenemases, such as Klebsiella Pneumoniae Carbapenemase (KPC) and New Delhi Metallo-β-lactamase (NDM), has severely limited the utility of last-resort antibiotics. Similarly, Aminoglycoside-Modifying Enzymes (AMEs) alter the structure of aminoglycosides, reducing their ability to bind bacterial ribosomes. In parallel, bacteria employ efflux pumps, such as those in the Resistance-Nodulation-Division (RND) family, to actively expel antibiotics from the cell, lowering intracellular drug concentrations below therapeutic levels. These molecular defenses, often encoded on plasmids and mobile genetic elements, facilitate rapid dissemination of resistance traits across species and geographical boundaries. Addressing AMR requires innovative strategies that target its molecular underpinnings while minimizing selective pressure for further resistance [2].

Target modification represents another major mechanism by which pathogens acquire resistance. Antibiotics exert their effects by binding to essential microbial targets, but mutations or chemical modifications in these targets can prevent drug binding. For example, mutations in DNA gyrase and topoisomerase IV confer resistance to fluoroquinolones, while alterations in penicillin-binding proteins underlie methicillin resistance in *Staphylococcus aureus*. Ribosomal RNA methylation, mediated by *erm* genes, confers resistance to macrolides, lincosamides, and streptogramins by blocking antibiotic binding to ribosomal subunits. In *Mycobacterium tuberculosis*, resistance to rifampicin, a cornerstone drug in tuberculosis therapy, arises from mutations in the *rpoB* gene encoding the RNA polymerase β-subunit. These molecular adaptations highlight the extraordinary capacity of microbes to reprogram their cellular machinery in response to selective pressures imposed by antimicrobial agents [3].

The spread of AMR is further accelerated by Horizontal Gene Transfer (HGT), a molecular process that enables rapid dissemination of resistance determinants within microbial communities. Conjugation, transformation, and transduction allow bacteria to acquire resistance genes from plasmids, integrons, and bacteriophages. Integrons, in particular, serve as genetic platforms that capture and express resistance gene cassettes, contributing to multidrug resistance in clinical pathogens. The global rise of mobile colistin resistance genes exemplifies the dangers of HGT, as colistin has been considered a last-line defense against MDR Gram-negative bacteria. Beyond bacteria, similar mechanisms operate in other pathogens, such as antifungal resistance mediated by *ERG11* mutations and efflux pump overexpression in *Candida* species. The ability of pathogens to share and accumulate resistance genes across environments underscores the urgent need for surveillance systems that track the molecular epidemiology of AMR. At the same time, CRISPR-Cas systems are being harnessed to selectively eliminate resistance genes from bacterial populations, representing a revolutionary approach to combating AMR at the genetic level [4,5].

Conclusion

Antimicrobial resistance is rooted in sophisticated molecular mechanisms that allow pathogens to neutralize drugs, modify targets, and share resistance determinants across ecosystems. The challenge of AMR lies not only in the adaptability of microbes but also in the global misuse of antimicrobials that accelerates this process. Future strategies must integrate molecular insights with interdisciplinary approaches, combining novel therapeutics, microbiome modulation, precision diagnostics, and robust stewardship programs. Global cooperation is essential, as AMR is not confined to borders but represents a shared threat to human, animal, and environmental health. By embracing next-generation technologies and promoting responsible antimicrobial use, it is possible to mitigate the spread of resistance and preserve the efficacy of life-saving therapies.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Zheng L, Jiang Z, Wang Z, Li Y, Jiao X, et al. (2023). The prevalence of Staphylococcus aureus and the emergence of livestock-associated MRSA CC398 in pig production in eastern China. Front Microbiol 14: 1267885.

2. Gomez-Sanz E, Ceballos S, Ruiz-Ripa L, Zarazaga M, Torres C (2019). Clonally diverse methicillin and multidrug resistant coagulase negative staphylococci are ubiquitous and pose transfer ability between pets and their owners. Front Microbiol 10: 485.

3. Dashtbani-Roozbehani A, Brown MH (2021). Efflux pump mediated antimicrobial resistance by staphylococci in health-related environments: Challenges and the quest for inhibition. Antibiotics 10: 1502.

4. Schijffelen MJ, Boel CE, van Strijp JA, Fluit AC (2010). Whole genome analysis of a livestock-associated methicillin-resistant *Staphylococcus aureus* ST398 isolate from a case of human endocarditis. BMC Genom 11: 376.

5. Cuny C, Wieler LH, Witte W (2015). Livestock-associated MRSA: The impact on humans. Antibiotics 4: 521-543.